Nurix Therapeutics Inc (NRIX) — Cash Flow-to-Debt Ratio
Nurix Therapeutics Inc (NRIX) has a Cash Flow-to-Debt Ratio of -0.38x as of August 2025, meaning its operating cash flow of $-57.38 Million could theoretically repay 0% of its total liabilities ($150.22 Million) in one year. See Nurix Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Nurix Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2024)
Historical debt coverage capacity for Nurix Therapeutics Inc across 7 annual periods. Also explore Nurix Therapeutics Inc (NRIX) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Nurix Therapeutics Inc (2018–2024)
Year-by-year debt coverage analysis for Nurix Therapeutics Inc. For market capitalisation and broader financial context, see Nurix Therapeutics Inc (NRIX) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.21x | $-172.58 Million | $142.35 Million | ▼ -131.1% |
| 2023 | -0.52x | $-81.36 Million | $155.10 Million | ▲ +62.9% |
| 2022 | -1.41x | $-159.81 Million | $113.06 Million | ▼ -125.3% |
| 2021 | -0.63x | $-84.36 Million | $134.47 Million | ▼ -83087.7% |
| 2020 | 0.00x | $-80.00K | $106.07 Million | ▼ -106.7% |
| 2019 | 0.01x | $601.00K | $53.57 Million | ▲ +101.2% |
| 2018 | -0.93x | $-31.68 Million | $34.05 Million | — |